A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy

NCT01517880 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

GNE Myopathy
Hereditary Inclusion Body Myopathy

Interventions

DRUG: Sialic Acid Extended Release (SA-ER)
DRUG: Placebo

Sponsor

Ultragenyx Pharmaceutical Inc